$0.0511
0[0.00%]
At close: Apr 22
Bellerophon Therapeutics
(OTCPK:BLPH)Bellerophon Therapeutics Stock (OTC:BLPH), Analyst Ratings, Price Targets, Predictions
Bellerophon Therapeutics Inc has a consensus price target of $1, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Laidlaw & Co., and HC Wainwright & Co. on June 6, 2023, June 6, 2023, and May 17, 2023. With an average price target of $10.67 between HC Wainwright & Co., Laidlaw & Co., and HC Wainwright & Co., there's an implied 20774.10% upside for Bellerophon Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Laidlaw & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bellerophon Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06/06/2023 | BLPH | Buy Now | Bellerophon Therapeutics | $0.05 | 3813.89% | HC Wainwright & Co. | Andrew Fein | $30 → $2 | Maintains | Buy | Get Alert |
| 06/06/2023 | BLPH | Buy Now | Bellerophon Therapeutics | $0.05 | — | Laidlaw & Co. | Yale Jen | — | Downgrade | Buy → Hold | Get Alert |
| 05/17/2023 | BLPH | Buy Now | Bellerophon Therapeutics | $0.05 | 58608.41% | HC Wainwright & Co. | Andrew Fein | → $30 | Reinstates | Buy → Buy | Get Alert |
| 05/09/2023 | BLPH | Buy Now | Bellerophon Therapeutics | $0.05 | 68393.15% | Laidlaw & Co. | Yale Jen | → $35 | Initiates | → Buy | Get Alert |
| 04/04/2023 | BLPH | Buy Now | Bellerophon Therapeutics | $0.05 | 58608.41% | HC Wainwright & Co. | Andrew Fein | → $30 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Bellerophon Therapeutics (BLPH)?
The latest price target for Bellerophon Therapeutics (OTCPK: BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 3813.89% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bellerophon Therapeutics (BLPH)?
The latest analyst rating for Bellerophon Therapeutics (OTCPK: BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics maintained their buy rating.
When was the last upgrade for Bellerophon Therapeutics (BLPH)?
There is no last upgrade for Bellerophon Therapeutics.
When was the last downgrade for Bellerophon Therapeutics (BLPH)?
The last downgrade for Bellerophon Therapeutics Inc happened on June 6, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Bellerophon Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Bellerophon Therapeutics (BLPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.
Is the Analyst Rating Bellerophon Therapeutics (BLPH) correct?
While ratings are subjective and will change, the latest Bellerophon Therapeutics (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics (BLPH) is trading at is $0.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.